Screener
Gyre Therapeutics, Inc. GYRE Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Gyre Pharmaceuticals | $29.1M+8.7% | $22.52M+2.1% | $37.2M+33.4% | $30.56M+19.9% | $26.77M+6.1% | |
| Gyre | $8K-99.7% | $0— | —— | —— | $2.96M— | |
| Revenue (Gross) by Product | ||||||
| Collaborations | $8K-99.7% | —— | —— | —— | $2.96M— | |
| Contiva | $883K-41.1% | $849+204% | $2.5M— | $1.25M— | $1.5M— | |
| Etorel | $255K-84.0% | $672— | $1.48M— | $1.54M— | $1.6M— | |
| Other Product | $30.97K-80.4% | $31-57.5% | $72.93K-52.3% | $81K-60.1% | $158K— | |
| Square Meter Area For Laboratory Center Under Lease by Geography | ||||||
| Nanjing | 700.0% | 700.0% | 70— | 70— | 70— | |
| Shanghai | 2240.0% | 2240.0% | 224— | 224— | 224— | |
| Zhengzhou | 1800.0% | 1800.0% | 180— | 180— | 180— |
FAQ
- How does Gyre Therapeutics, Inc. break its business down?
- Gyre Therapeutics, Inc. (GYRE) reports revenue by business across 2 parts — Gyre Pharmaceuticals and Gyre. Each is extracted from the segment footnotes and tracked over time.
- Where does Gyre Therapeutics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Gyre Therapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
